fda glp 1 compounding New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA and Novo Nordisk Warned

Therefore, therapies capable of producing sustained weight reduction may substantially alter disease progression rather than simply treating elevated glucose levels

5.3 Granules India Limited Date of Issuance: February 26, 2025 Location: Dundigal-Gandimaisamma Mandal, India Product Type: Finished Pharmaceuticals Main Citation Concerns with CGMP records A large amount of torn CGMP records were discovered in at least 15 plastic waste bags during the inspection, including analytical balance printouts and worksheets containing manufacturing and testing data

[DOI] [PubMed] [Google Scholar] [75].Chaudhury C, Mehnaz S, Robinson JM, Hayton WL, Pearl DK, Roopenian DC, Anderson CL, The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan, The Journal of experimental medicine, 197 (2003) 315322

One year of sitagliptin treatment protects against islet amyloid-associated beta-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice

These physiological alterations yield atypical patterns of tracer uptake, complicating the clear differentiation between malignant versus benign or inflammatory processes